Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review
Immune checkpoint inhibitors (ICI), such as pembrolizumab, nivolumab, durvalumab and ipilimumab, have significantly enhanced survival rates for multiple cancer types such as non-small cell lung cancer, melanoma, Hodgkin lymphoma, and breast cancer, and they have emerged as an adjunct or primary ther...
Saved in:
| Main Authors: | Chang Li, Saadia A. Faiz, Megan Boysen-Osborn, Ajay Sheshadri, Monica K. Wattana |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
eScholarship Publishing, University of California
2025-02-01
|
| Series: | Western Journal of Emergency Medicine |
| Online Access: | https://escholarship.org/uc/item/8jb3v6kf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic immune checkpoint inhibitor pneumonitis
by: Julie R Brahmer, et al.
Published: (2020-05-01) -
Antibody-Drug Conjugate-Induced Pneumonitis: A Growing Threat
by: Kathy L. Chan, et al.
Published: (2025-04-01) -
Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitis
by: Mahnoor Mir, et al.
Published: (2025-06-01) -
Correction: Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitis
by: Mahnoor Mir, et al.
Published: (2025-06-01) -
Managing Immune Checkpoint Inhibitor Pneumonitis in the ICU
by: Kristina Montemayor, MD, MHS, et al.
Published: (2025-03-01)